{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T05:02:46Z","timestamp":1783227766528,"version":"3.54.6"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T00:00:00Z","timestamp":1674000000000},"content-version":"am","delay-in-days":323,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000139","name":"U.S. Environmental Protection Agency","doi-asserted-by":"publisher","award":["STAR RD83580201"],"award-info":[{"award-number":["STAR RD83580201"]}],"id":[{"id":"10.13039\/100000139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000066","name":"National Institute of Environmental Health Sciences","doi-asserted-by":"publisher","award":["P42 ES027704"],"award-info":[{"award-number":["P42 ES027704"]}],"id":[{"id":"10.13039\/100000066","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000066","name":"National Institute of Environmental Health Sciences","doi-asserted-by":"publisher","award":["T32 ES026568"],"award-info":[{"award-number":["T32 ES026568"]}],"id":[{"id":"10.13039\/100000066","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological and Toxicological Methods"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.vascn.2022.107154","type":"journal-article","created":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T05:24:21Z","timestamp":1641446661000},"page":"107154","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["A tiered approach to population-based in vitro testing for cardiotoxicity: Balancing estimates of potency and variability"],"prefix":"10.1016","volume":"114","author":[{"given":"Alexander D.","family":"Blanchette","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah D.","family":"Burnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Rusyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihsueh A.","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.vascn.2022.107154_bb0005","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1289\/ehp.1408775","article-title":"Population-based in vitro hazard and concentration\u2013response assessment of chemicals: The 1000 genomes high-throughput screening study","volume":"123","author":"Abdo","year":"2015","journal-title":"Environmental Health Perspectives"},{"issue":"4","key":"10.1016\/j.vascn.2022.107154_bb0010","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/01.hjr.0000173110.21851.a9","article-title":"Risk factors for prolonged QTc among US adults: Third National Health and nutrition examination survey","volume":"12","author":"Benoit","year":"2005","journal-title":"European Journal of Cardiovascular Prevention and Rehabilitation"},{"issue":"2","key":"10.1016\/j.vascn.2022.107154_bb0015","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/toxsci\/kfaa151","article-title":"A Bayesian method for population-wide cardiotoxicity Hazard and risk characterization using an in vitro human model","volume":"178","author":"Blanchette","year":"2020","journal-title":"Toxicological Sciences"},{"issue":"5","key":"10.1016\/j.vascn.2022.107154_bb0020","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1002\/cpt.1259","article-title":"Thorough QT\/QTc in a dish: An in vitro human model that accurately predicts clinical concentration-QTc relationships","volume":"105","author":"Blanchette","year":"2019","journal-title":"Clinical Pharmacology & Therapeutics"},{"issue":"6","key":"10.1016\/j.vascn.2022.107154_bb0025","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/cts.12674","article-title":"Clinical trial in a dish: Personalized stem cell-derived cardiomyocyte assay compared with clinical trial results for two QT-prolonging drugs","volume":"12","author":"Blinova","year":"2019","journal-title":"Clinical and Translational Science"},{"issue":"1","key":"10.1016\/j.vascn.2022.107154_bb0030","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/toxsci\/kfw200","article-title":"Comprehensive translational assessment of human-induced pluripotent stem cell derived cardiomyocytes for evaluating drug-induced arrhythmias","volume":"155","author":"Blinova","year":"2017","journal-title":"Toxicological Sciences"},{"key":"10.1016\/j.vascn.2022.107154_bb0035","doi-asserted-by":"crossref","DOI":"10.1080\/17425255.2021.1894122","article-title":"Human induced pluripotent stem cell (iPSC)-derived cardiomyocytes as an in vitro model in toxicology: Strengths and weaknesses for hazard identification and risk characterization","author":"Burnett","year":"2021","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.vascn.2022.107154_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2019.114711","article-title":"Population-based toxicity screening in human induced pluripotent stem cell-derived cardiomyocytes","volume":"381","author":"Burnett","year":"2019","journal-title":"Toxicology and Applied Pharmacology"},{"issue":"5","key":"10.1016\/j.vascn.2022.107154_bb0045","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nm.4087","article-title":"Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity","volume":"22","author":"Burridge","year":"2016","journal-title":"Nature Medicine"},{"issue":"4","key":"10.1016\/j.vascn.2022.107154_bb0050","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1007\/s12012-014-9300-0","article-title":"Evolving electrocardiographic changes in lamotrigine overdose: A case report and literature review","volume":"15","author":"Chavez","year":"2015","journal-title":"Cardiovascular Toxicology"},{"issue":"1\u20132","key":"10.1016\/j.vascn.2022.107154_bb0055","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s00335-017-9731-6","article-title":"Advancing chemical risk assessment decision-making with population variability data: Challenges and opportunities","volume":"29","author":"Chiu","year":"2018","journal-title":"Mammalian Genome"},{"issue":"3","key":"10.1016\/j.vascn.2022.107154_bb0060","doi-asserted-by":"crossref","first-page":"377","DOI":"10.14573\/altex.1608251","article-title":"A tiered, Bayesian approach to estimating of population variability for regulatory decision-making","volume":"34","author":"Chiu","year":"2017","journal-title":"ALTEX"},{"issue":"11","key":"10.1016\/j.vascn.2022.107154_bb0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1000287","article-title":"Genetic analysis of human traits in vitro: Drug response and gene expression in Lymphoblastoid cell lines","volume":"4","author":"Choy","year":"2008","journal-title":"PLoS Genetics"},{"issue":"3","key":"10.1016\/j.vascn.2022.107154_bb0070","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/j.1365-2125.2008.03250.x","article-title":"Lamotrigine does not prolong QTc in a thorough QT\/QTc study in healthy subjects","volume":"66","author":"Dixon","year":"2008","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"2","key":"10.1016\/j.vascn.2022.107154_bb0075","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1093\/toxsci\/kfw128","article-title":"The influence of human Interindividual variability on the low-dose region of dose-response curve induced by 2,3,7,8-Tetrachlorodibenzo-p-dioxin in primary B cells","volume":"153","author":"Dornbos","year":"2016","journal-title":"Toxicological Sciences"},{"issue":"8","key":"10.1016\/j.vascn.2022.107154_bb0080","first-page":"765","article-title":"Clinical trials in a dish: A perspective on the coming revolution in drug development. SLAS DISCOVERY: Advancing the science of","volume":"23","author":"Fermini","year":"2018","journal-title":"Drug Discovery"},{"issue":"4","key":"10.1016\/j.vascn.2022.107154_bb0085","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1214\/ss\/1177011136","article-title":"Inference from iterative simulation using multiple sequences","volume":"7","author":"Gelman","year":"1992","journal-title":"Statistical Science"},{"issue":"6","key":"10.1016\/j.vascn.2022.107154_bb0090","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1016\/j.stemcr.2017.05.012","article-title":"Taming human genetic variability: Transcriptomic Meta-analysis guides the experimental design and interpretation of iPSC-based disease modeling","volume":"8","author":"Germain","year":"2017","journal-title":"Stem Cell Reports"},{"key":"10.1016\/j.vascn.2022.107154_bb0095","doi-asserted-by":"crossref","unstructured":"Grimm, F. A., Blanchette, A., House, J. S., Ferguson, K., Hsieh, N. H., Dalaijamts, C., Wright, A. A., Anson, B., Wright, F. A., Chiu, W. A., & Rusyn, I. (2018, Jul 8). A human population-based organotypic in vitro model for cardiotoxicity screening. ALTEX, 35(4), 441-452. Doi: 10.14573\/altex.1805301.","DOI":"10.14573\/altex.1805301"},{"issue":"1","key":"10.1016\/j.vascn.2022.107154_bb0100","doi-asserted-by":"crossref","DOI":"10.1186\/s12929-019-0578-x","article-title":"Human iPSC banking: Barriers and opportunities","volume":"26","author":"Huang","year":"2019","journal-title":"Journal of Biomedical Science"},{"key":"10.1016\/j.vascn.2022.107154_bb0105","series-title":"ICH E14 guideline: The clinical evaluation of QT\/QTc interval prolongation and Proarrhythmic potential for non-antiarrhythmic drugs questions & answers (R3)","author":"ICH","year":"2015"},{"issue":"7658","key":"10.1016\/j.vascn.2022.107154_bb0110","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/nature22403","article-title":"Common genetic variation drives molecular heterogeneity in human iPSCs","volume":"546","author":"Kilpinen","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.vascn.2022.107154_bb0115","first-page":"7","article-title":"Determining the genetic basis of anthracycline-cardiotoxicity by molecular response QTL mapping in induced cardiomyocytes","author":"Knowles","year":"2018","journal-title":"eLife"},{"issue":"4","key":"10.1016\/j.vascn.2022.107154_bb0120","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/j.1476-5381.2011.01255.x","article-title":"How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines?","volume":"163","author":"Laverty","year":"2011","journal-title":"British Journal of Pharmacology"},{"issue":"2","key":"10.1016\/j.vascn.2022.107154_bb0125","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/toxsci\/kfs023","article-title":"Quantitative high-throughput screening for chemical toxicity in a population-based in vitro model","volume":"126","author":"Lock","year":"2012","journal-title":"Toxicological Sciences"},{"issue":"7","key":"10.1016\/j.vascn.2022.107154_bb0130","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1289\/ehp.1510267","article-title":"CERAPP: Collaborative estrogen receptor activity prediction project","volume":"124","author":"Mansouri","year":"2016","journal-title":"Environmental Health Perspectives"},{"issue":"3","key":"10.1016\/j.vascn.2022.107154_bb0135","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1161\/CIRCRESAHA.111.250266","article-title":"Induced pluripotent stem cells in cardiovascular drug discovery","volume":"112","author":"Mercola","year":"2013","journal-title":"Circulation Research"},{"issue":"7","key":"10.1016\/j.vascn.2022.107154_bb0140","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3109\/15563650.2013.818685","article-title":"A case series of patients with lamotrigine toxicity at one center","volume":"51","author":"Moore","year":"2013","journal-title":"Clinical Toxicology (Philadelphia, Pa.)"},{"issue":"2","key":"10.1016\/j.vascn.2022.107154_bb0145","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/toxsci\/kfq322","article-title":"In vitro screening for population variability in chemical toxicity","volume":"119","author":"O\u2019Shea","year":"2011","journal-title":"Toxicological Sciences"},{"key":"10.1016\/j.vascn.2022.107154_bb0150","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.cotox.2020.04.001","article-title":"Toxicity testing in the era of induced pluripotent stem cells: A perspective regarding the use of patient-specific induced pluripotent stem cell\u2013derived cardiomyocytes for cardiac safety evaluation","volume":"23-24","author":"Pang","year":"2020","journal-title":"Current Opinion in Toxicology"},{"key":"10.1016\/j.vascn.2022.107154_bb0155","series-title":"Modeling susceptibility to drug-induced long QT with a panel of subject-specific induced pluripotent stem cells","volume":"6","author":"Stillitano","year":"2017"},{"issue":"5","key":"10.1016\/j.vascn.2022.107154_bb0160","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1002\/cpt.1384","article-title":"Thorough QT\/QTc in a dish: Can human induced pluripotent stem cell-derived cardiomyocytes predict thorough QT outcomes?","volume":"105","author":"Vargas","year":"2019","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"1","key":"10.1016\/j.vascn.2022.107154_bb0165","doi-asserted-by":"crossref","first-page":"dmm042317","DOI":"10.1242\/dmm.042317","article-title":"Addressing variability in iPSC-derived models of human disease: Guidelines to promote reproducibility","volume":"13","author":"Volpato","year":"2020","journal-title":"Disease Models & Mechanisms"},{"issue":"1","key":"10.1016\/j.vascn.2022.107154_bb0170","doi-asserted-by":"crossref","DOI":"10.3390\/data5010010","article-title":"An open-access dataset of thorough QT studies results","volume":"5","author":"Wi\u015bniowska","year":"2020","journal-title":"Data"},{"issue":"1","key":"10.1016\/j.vascn.2022.107154_bb0175","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41588-018-0295-5","article-title":"A primer on deep learning in genomics","volume":"51","author":"Zou","year":"2019","journal-title":"Nature Genetics"}],"container-title":["Journal of Pharmacological and Toxicological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056871922000016?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056871922000016?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:04:50Z","timestamp":1761005090000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056871922000016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":35,"alternative-id":["S1056871922000016"],"URL":"https:\/\/doi.org\/10.1016\/j.vascn.2022.107154","relation":{},"ISSN":["1056-8719"],"issn-type":[{"value":"1056-8719","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A tiered approach to population-based in vitro testing for cardiotoxicity: Balancing estimates of potency and variability","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological and Toxicological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vascn.2022.107154","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107154"}}